For peptide-led practices · phenotype-matched, with an AVOID list

Stop stacking peptides by goal. Match them to phenotype.

Multi-peptide cycles run $795–$1,295 and churn the moment a response is slow. CellWise ranks commercially available peptides against each patient's single-cell phenotype, so you get an explicit AVOID list and a transcriptomic reason to defend every 503A protocol. What gets compared, and what lands on the AVOID list, follows the phenotype and so varies with the patient.

See what it costs
✓ Founding pilot rate: $1,800 a patient ✓ Founder pricing ✓ No repeat sequencing to keep using it
CellWise · Peptide Compatibility Engine
Peptide Atlas · matched
BPC-157 ✓
AVOID · GHRH analog
CJC-1295
Immuno-metabolic phenotype
Glycolytic / inflammatoryOxidative / quiescent
Alert rules · 88 peptides
519
Clinical Surveillance Feed
Active ✓
Why this call
Inflammatory phenotype → GH secretagogues flagged for glucose intolerance & fluid retention
Grounded inreal population datapeer-reviewed researchlegacy single-cell technology
Founding Practitioner Pilot · fifty places

Up to five of your own patients at $2,095 $1,800 each, for Core Plus.

14% below standard Invoiced only for the ones you send.All in: kit, shipping and the blood draw.A sample that fails lab QC is not invoiced.Decide at the end of a 30-day review.
Per patient
$1,800

Core Plus, 14% below the $2,095 standard rate.

How many
One to five

Your own patients. Invoiced only for the ones you send.

Billing
On delivery, net 30

All in: collection kit, shipping and the phlebotomy draw. A failed QC sample is not invoiced.

Your decision
30-day review

Full module access from your last report, then decide whether to carry on.

Fifty founding places.Full pricing and terms
What it actually solves

The three things that churn a peptide practice.

Each one is a place you lose a patient, a cycle, or a night of sleep. Here's what CellWise does about it.

$795–1,295 stacks that don't land

Multi-peptide cycles are expensive, and patients churn the moment a response is slow. CellWise ranks commercially available peptides against each patient's cellular phenotype, with the rationale for each ranking and an explicit AVOID list, so you build the stack on molecular fit instead of a generalized goal. The ranking and the AVOID list follow the phenotype, so they vary with the patient.

Fewer wasted cycles, fewer patients out the door

Prescribing by intuition, not data

Peptide selection has always leaned on clinical instinct. The immuno-metabolic axis and an explicit AVOID list give you an objective, transcriptomic reason for every compound you start or hold.

A defensible basis for every call

503A rules tightening under you

The FDA is actively restricting BPC-157, TB-500, KPV, and MOTS-c. CellWise puts a transcriptomic justification on file for every off-label protocol, so your compliance posture keeps up with the compounding landscape.

Documentation that moves as fast as the rules
Rotates every few seconds. Hover to pause, click a headline to hold it.
Before you pair a peptide, see which pathways are already switched on.

Interferon and inflammasome programmes decide whether a peptide fits or waits. Real data from 26 reference donors with no known diagnosis: each column is one person, each row one gene in one immune cell type, coloured against people of the same sex.

Interferon response on in 4 of 26 donors 26 reference donors, no known diagnosis. One column per person. Interferon response ↑ switched on when the state is present ISG15 · CD16 monocytes IFIT2 · CD16 monocytes IRF7 · CD16 monocytes OAS1 · CD16 monocytes OAS1 · CD14 monocytes Inflammasome and IL-1 ↑ switched on when the state is present IL1B · CD14 monocytes CXCL8 · CD14 monocytes NLRP3 · CD14 monocytes CASP1 · CD14 monocytes
Lower than reference Higher than reference not read Robust z-score of each gene in its cell type against same-sex reference donors (colour capped at ±5). Hover a square for the value.
  • Interferon on: CellWise holds immune-activating peptides such as LL-37 and thymosin alpha-1 until the programme settles.
  • Inflammasome on: the state that GLP-1 receptor agonists and KPV are mapped to act on, read in the monocytes that carry it.
  • Neither shows on a standard panel. Both are switch positions inside cells, read before a symptom or a serum marker moves.
Everything in the portal

Seven modules, one clinical workspace.

Health Analysis ReportIllustrative preview
SemaglutideGLP-1 receptor agonist · mapped with tirzepatide
Strong match
  1. Cell stateInnate inflammation on, in CD14 monocytes
  2. Genes4 move with the state, 1 against
  3. PathwayNF-κB and IL-1β
  4. MechanismLowered IL-1β and TNF in mononuclear cells in a randomised trial; pooled trials lower CRP. Human data
  5. Check firstA recent infection or vaccine, or hard exercise before the draw
In line with the state
IL1B ↑CXCL8 ↑NLRP3 ↑TNF ↑
Moving against it
CCL2 ↓

Read in this patient's CD14 monocytes against people of the same sex in the reference set.

Mechanism: human dataResponse: CellWise prediction, not yet validated
Module 01

Health Analysis Report

The clinical home base: risk-rated health domains, immuno-metabolic phenotyping, and mechanism-based peptide pairing, each call traced from cell state to genes, pathway and mechanism.

Clinicians see
Each peptide call explained: the cell state, the genes moving with it and against it, the pathway, the evidence tier and what to check first.
Licensees get
Report templates in your brand, under co-brand or white-label.
Biomarker AnalyticsIllustrative preview
S100A12
IL1B
ISG15
CCR7
TCF7
PRF1
HSPA5
same-sex reference rangethis patient
Module 02

Biomarker Analytics

The quantitative, visual view of the patient's raw biomarker data, shown as a population-vs-patient overview.

Clinicians see
Every panel gene placed against the same-sex reference population, the outliers first.
Licensees get
The same views themed to your interface, or piped through the API.
Data ExplorerIllustrative preview
IL1B
Cell populationDirectionSignal
CD14 monocytes↑
CD16 monocytes↑
pDCs↑
CD4 T cells·
Module 03

Data Explorer

A filterable, gene-level interface over the patient's complete dataset, exposing the top cell populations carrying each signal.

Clinicians see
Filter by gene, cell type or direction and see which populations carry each signal.
Licensees get
Gene-level data your scientific team can query, not just a PDF.
Clinical Scenario SimulatorIllustrative preview
HypothesisWhat if this patient starts a GLP-1 receptor agonist?
Re-running against this patient's data
Inflammasome tone
Insulin signalling
Interferon response
Module 04

Clinical Scenario Simulator

Test a clinical hypothesis against the patient's own molecular data and re-run it in seconds.

Clinicians see
Pose a clinical hypothesis against the patient's own data and re-run it in seconds.
Licensees get
A consult tool that keeps clinicians working inside your platform.
Outcomes & MonitoringIllustrative preview
BaselineLoadingMaintenance
Peptide-specific labWearable trend (HRV)
Module 05

Outcomes & Monitoring

Assay-independent surveillance across dosing phases, peptide-specific labs, and wearable trends, with no repeat sequence required.

Clinicians see
Peptide-specific labs and wearable trends tracked across dosing phases, between screens.
Licensees get
A monitoring loop that brings patients back to your menu between draws.
Cellular Aging ProfileIllustrative preview
Immune agewhich compartments are aging fastest, and which hallmarks drive it
Genomic instabilityTelomere attritionEpigenetic alterationProteostasisAutophagyNutrient sensingMitochondriaSenescenceStem-cell exhaustionCommunicationInflammationDysbiosis
Module 06

Cellular Aging Profile

Immune age, senescence, and the 12 hallmarks from one PBMC sample, for cell-resolved biological aging.

Clinicians see
Immune age, senescence and the 12 hallmarks of aging from one PBMC sample.
Licensees get
A preventative-health line item you can list under your own name.
Longitudinal ScreeningIllustrative preview
IL1B · CD14 mono
↓
ISG15 · CD16 mono
·
CCR7 · CD4 T
↑
DDIT3 · NK
↓
Screen 1Screen 2
Module 07

Longitudinal Screening

Re-assay a patient and see the gene-expression deltas across key biomarkers, so you see what has shifted since the last screen.

Clinicians see
Re-assay and see exactly which genes moved, in which cells, since the last screen.
Licensees get
Re-assay built into the product, so the second test is part of the plan.
Hover or tap a module to stop on it. Previews are illustrative.
What the beta measured

Numbers a cash-pay practice can feel.

Reviewers read the same donor in isolation and converged on the same compound match, the same AVOID call, and the same follow-up labs.

$795–1,295
Per multi-peptide cycle at risk. The AVOID list keeps you from spending it on a compound the phenotype rejects.
≥1
Contraindicated peptide prevented per complex patient, like GHRH analogs withheld in a hyper-inflammatory state.
519 alert rules
Across 88 peptides in the post-therapy monitoring library, built from regulatory and clinical efficacy data, so a compound you start is watched after it starts. Compatibility ranking is separate: it runs against commercially available peptides and varies with the patient.
45→15 min
Chart prep on a complex patient, with hours of clinical time recovered each week across a full roster.
503A
A transcriptomic justification on file for every off-label protocol as compounding rules tighten.
Live
A Clinical Surveillance Feed tracking dosing phases and peptide-specific labs, for confidence at every point in care with no repeat sequence.
From the review room

Same donor. Same AVOID call. No cross-talk.

“

The GLP-1/GIP recommendation is well-grounded. I would have considered semaglutide for metabolic reasons anyway, but the PBMC mechanistic context (GLP-1R on monocytes reducing pro-inflammatory cytokine secretion) gives me a molecular rationale to present to the patient that increases adherence.

Peptide NMD
Beta review
“

Placing the patient on the glycolytic–oxidative axis before I build a stack is exactly the objective baseline peptide prescribing has always been missing.

Integrative Wellness MD
Beta review
“

Having a transcriptomic reason for each AVOID call is the difference between defending a 503A protocol and hoping no one asks.

Regenerative Medicine DO
Beta review
◆ Illustrative, not testimonial. These show the kind of read the report supports, drafted from clinician personas during beta design rather than quoted from named practitioners. Reviews from the founding pilot will replace them.

Baseline up to five patients, at the founding rate.

Join the founding pilot: up to five of your own patients at $1,800 each, 14% below the standard rate, invoiced only for the ones you send. Founding rates lock for twelve months if you go forward, and every pilot practice is a design partner with a say on what gets built. Open to a limited cohort of high-volume peptide practices.